Algernon Pharmaceuticals (XCNQ:AGN) EPS (Basic) : C$-0.42 (TTM As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals EPS (Basic)?

Algernon Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Nov. 2023 was C$-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Nov. 2023 was C$-0.42.

Algernon Pharmaceuticals's EPS (Diluted) for the three months ended in Nov. 2023 was C$-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2023 was C$-0.42.

Algernon Pharmaceuticals's EPS without NRI for the three months ended in Nov. 2023 was C$-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2023 was -0.42.

During the past 3 years, the average EPS without NRI Growth Rate was 44.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Algernon Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 53.50% per year. The lowest was -63.10% per year. And the median was -0.90% per year.

Algernon Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Algernon Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals EPS (Basic) Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EPS (Basic)

Get a 7-Day Free Trial

-0.84

-2.03

-1.04

-0.87

-0.45

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
EPS (Basic)	Get a 7-Day Free Trial															-0.20	-0.13	-0.10	-0.16	-0.03

Algernon Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Algernon Pharmaceuticals's Basic EPS for the fiscal year that ended in Aug. 2023 is calculated as

Basic EPS (A: Aug. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.781	-	0)	/	15.147
	=	-0.45

Algernon Pharmaceuticals's Basic EPS for the quarter that ended in Nov. 2023 is calculated as

Basic EPS (Q: Nov. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.522	-	0)	/	15.776
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.42

Algernon Pharmaceuticals (XCNQ:AGN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Algernon Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines